Picture [iito] Made Without Love 650x80px
Organisation › Details

Lysogene S.A. (Euronext Paris: LYS)

Lysogene is a clinical-stage biotechnology company pioneering in the basic research and clinical development of gene therapies that use vectors derived from adeno-associated viruses to treat rare and fatal central nervous system disorders in children, for which, to the best of the Company’s knowledge, there is currently no treatment. Since 2009, Lysogene has established a solid platform and extensive network, along with innovative products in MPS IIIA and GM1 gangliosidosis, to become a global leader in gene therapies for rare and fatal central nervous system diseases. *


Period Start 2009-05-13 established
Products Industry BIOTECH
  Industry 2 gene therapy
Persons Person Aiach, Karen (Lysogene 201206 CEO + Founder)
  Person 2 Durant des Aulnois, Stéphane (Lysogene 201910– CFO before Ipsen + LaSalle Investment + Calyon Americas)
Region Region Paris
  Country France
  Street 18–20 rue Jacques Dulud
  City 92200 Neuilly-sur-Seine
  Tel +33-1-4143-0390
    Address record changed: 2020-12-02
Basic data Employees n. a.
  Currency EUR
  Profit -7,484,000 (2016-12-31)
  Cash 6,353,000 (2016-12-31)
    * Document for �About Section�: Lysogene S.A.. (1/25/17). "Press Release: Lysogene Launches Its IPO on Euronext’s Regulated Market in Paris".
Record changed: 2020-07-14


Picture [iito] Made Without Love 650x80px

More documents for Lysogene S.A. (Euronext Paris: LYS)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Hotspot for Startups 650x80px

» top